Category: pyridazine

65202-50-8, Methyl 6-chloropyridazine-3-carboxylate is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

65202-50-8, 6-(3,6-Dihydro-2H-pyran-4-yl)pyridazin-3-carboxylic Acid Methyl 6-chloropyridazine-3-carboxylate (1.00 g, 5.79 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyran (1.22 g, 5.79 mmol), Pd(PPh3)4 (536 mg, 0.44 mmol) and Cs2CO3 (3.40 g, 10.4 mmol) were suspended in dioxane (8 mL) and water (8 mL) and heated in a microwave reactor at 125¡ã C. for 30 min. 1M aq HCl (10 mL) was added, the precipitate was removed by filtration and the filtrate was concentrated in vacuo. The residue was passed through a silica pad eluting with 30percent MeOH in DCM and concentrated in vacuo to give the title compound as a white solid (946 mg, 79.2percent). LCMS (ES+): 207.1 [MH]+. HPLC: Rt 3.30 min, 49.9percent purity.

The synthetic route of 65202-50-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Proximagen Limited; Espensen, Max; Patient, Lee; Evans, David; Savory, Edward; Simpson, Iain; US2014/275040; (2014); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.187973-60-0,6-Iodopyridazin-3-amine,as a common compound, the synthetic route is as follows.

187973-60-0, General procedure: A 10 mL round-bottomed flask containing a magnetic stirbar was charged with CuI (0.1 mmol) followed by L-hydroxyproline (0.2 mmol),6-iodopyridazin-3-amine (1.3 mmol) and K3PO4 (3.0 mmol). The flask wasflushed with N2 and a solution of the appropriate amine (1.0 mmol) inanhydrous DMSO (1.5 mL) was then added. The mixture was stirred under N2at 50 C for 24 h. MeOH (5 mL) and H2O (5 mL) were added and the stirredmixture was neutralised by dropwise addition of AcOH. The resultant solidswere allowed to settle out and the supernatant solution added to the top of astrong cation exchange (SCX) column. The remaining solid was washed withfurther MeOH (5 mL), and the washings also added to the SCX column. Thesolution was allowed to elute slowly through the column, which was thenflushed with further MeOH. These MeOH washings were discarded. A 1 Msolution of NH3 in MeOH was flushed through until elution of the product wascomplete and the solvent was evaporated under reduced pressure to yield acrude material. Purification was done by flash silica chromatography, elutiongradient typically 0-10% MeOH in CH2Cl2. Relevant fractions were evaporatedto dryness to afford the desired product.

The synthetic route of 187973-60-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Bethel, Paul A.; Roberts, Bryan; Bailey, Andrew; Tetrahedron Letters; vol. 55; 37; (2014); p. 5186 – 5190;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

1121-79-5, 3-Chloro-6-methylpyridazine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Intermediate 4-(6-Chloro-pyridazin-3-yl)-cvclopropanecarbonitrileStep 1 : 3-chloro-6-chloromethyl-pyridazine; Trichloroisocyanuric acid (3.62 g) was added to a solution of 3-chloro-6-methyl-pyridazine (5.00 g) in chloroform (130 mL) heated to 60 C. The mixture was stirred at 60 1121-79-5

As the paragraph descriping shows that 1121-79-5 is playing an increasingly important role.

Reference£º
Patent; VITAE PHARMACEUTICALS, INC.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; LEFTHERIS, Katerina; ZHUANG, Linghang; TICE, Colin, M.; SINGH, Suresh, B.; YE, Yuanjie; XU, Zhenrong; HIMMELSBACH, Frank; ECKHARDT, Matthias; WO2011/159760; (2011); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6082-66-2,3,4,6-Trichloropyridazine,as a common compound, the synthetic route is as follows.

6082-66-2, To a solution of 3,4,6-trichloropyridazine (2.92 g, 15.90 mmol) and 2,2-dimethyl-l- methylsulfonyl-piperazine hydrochloride (4.0 g, 17.4 mmol) in DMA (40 mL) was added Na2CC”3 (3.37 g, 31.79 mmol), the mixture was stirred at 25 C for 2 h. To the mixture was added water (20 mL), extracted with EtOAc (10 mL x3), the combined organic layers were washed with brine (15 mL x2), dried over Na2S04, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (Si02, Petroleum ether/EtOAc=20/l to 3/1), to afford 3,6-dichloro-4-(3,3-dimethyl-4-methylsulfonyl-piperazin-l- yl)pyridazine (4.8 g, 10.61 mmol, 67 % yield) as a green solid. MS (ES+) CnHi6N4Cl202S requires: 338, found 339 [M+H]+.

6082-66-2 3,4,6-Trichloropyridazine 95123, apyridazine compound, is more and more widely used in various.

Reference£º
Patent; TESARO, INC.; LEWIS, Richard T.; JONES, Philip; PETROCCHI, Alessia; REYNA, Naphtali; HAMILTON, Matthew; CROSS, Jason; TREMBLAY, Martin; LEONARD, Paul Graham; (216 pag.)WO2018/136887; (2018); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.7252-84-8,3-Amino-6-methoxypyridazine,as a common compound, the synthetic route is as follows.

7252-84-8, To a solution of 6-Methoxy-pyridazin-3-ylamine (39 mg, 0.31 mmol, [Cas.No.7252-84-8]) in DMF (3 mL) at 0C was added sodium hydride (20 mg, 0.5 mmol, 60% disp. in mineral oil). After stirring at 0C for 15 min. a solution of 3-[5-(2-Fluoro-phenyl)-pyridin-2-yloxy]- azetidine-1 -carboxylic acid 4-nitro-phenyl ester (102 mg, 0.25 mmol) in DMF (4 mL) was added dropwise. After stirring for 16 hrs at ambient temperature the reaction mixture was concentrated in vacuo, diluted with ethyl acetate (50 ml.) and washed sequentially with sat. aqueous sodium hydrogen carbonate solution (2 x 50 mL) then sat. sodium chloride solution (50 mL). Mixture dried over magnesium sulphate and filtered. Filtrate solvents were removed in vacuo and the residue was purified by flash chromatography (ethyl acetate) to give the title compound (35 mg, 37%) LCMS: (Method A) RT = 1.97 min; m/z = 396 [M+H]+.1H NMR: (400 MHz, CDCI3) delta 4.03 (s, 3H), 4.21-4.25 (m, 2H), 4.55-4.59 (m, 2H), 5.45- 5.50 (m, 1H), 6.88 (d, 1H, J 8.6), 7.02 (d, 1H, J 9.6), 7.15-7.25 (m, 2H), 7.31-7.42 (m, 2H), 7.81-7.84 (m, 1H), 8.28 (bs, 1H), 8.35 (d, 1 H, J 9.3).

7252-84-8 3-Amino-6-methoxypyridazine 81673, apyridazine compound, is more and more widely used in various.

Reference£º
Patent; VERNALIS (R&D) LTD.; WO2009/109743; (2009); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

89203-22-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.89203-22-5,3-Aminopyridazine hydrochloride,as a common compound, the synthetic route is as follows.

2,8-dimethyl-6-(2-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazine-3-carboxylic acid (150.0 mg, 0.45 mmol) was dissolved in DMF (2.4 mL). HATU (255.0 mg, 0.67 mmol) was added, followed by diisopropylethylamine (0.312 mL, 1.79 mmol). 3-aminopyridazine-HCl (59.0 mg, 0.45 mmol) was slurried in DMF (2.4 mL) and diisopropylethylamine (0.078 mL, 0.45 mmol) and added to the reaction mixture. This was warmed to 60 C and allowed to stir under nitrogen atmosphere for 3.5 h. The mixture was cooled to room temp, and saturated aqueous NaHCO3 was added (6 mL), then water was added (10 mL). This was extracted with EtOAc (3×20 mL) and the combined organics were washed with brine, dried with anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography using a gradient of 0 – 10% MeOH in CH2Cl2 to give 2,8-dimethyl-N-(pyridazin-3-yl)-6-(2-(trifluoromethyl)phenyl) imidazo[1,2-b]pyridazine-3-carboxamide (19.6 mg, 11%). MS (ESI) calcd for C20H15F3N6O: 412.13; found: 413.2 [M+H].

89203-22-5 3-Aminopyridazine hydrochloride 73994943, apyridazine compound, is more and more widely used in various.

Reference£º
Patent; GlaxoSmithKline LLC; CASAUBON, Rebecca, L.; NARAYAN, Radha; OALMANN, Christopher; VU, Chi, B.; (583 pag.)EP2768509; (2017); B1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.90008-50-7,6-Propoxypyridazin-3-amine,as a common compound, the synthetic route is as follows.,90008-50-7

General procedure: A stirred mixture of 3-amino-6-propoxypyridazine 3 (4.50g, 29.4mmol), 2-bromo-1-[4-(2-methoxyethoxy)phenyl]ethanone 11 (8.03g, 29.4mmol) and EtOH (280mL) was heated at reflux for 2.5 hours. The mixture was cooled and NaHCO3 (2.50g, 30mmol) was added. The mixture was stirred at room temperature for 15 hours, heated at reflux for 1 hour, then cooled and evaporated. The residue was extracted with CHCl3 (150mL) and the extract washed with saturated, aqueous NaCl solution (50mL), dried (MgSO4) and evaporated. The residue was purified by flash chromatography over silica gel. Elution with 1-2% MeOH in CH2Cl2 afforded a green/brown solid. Treatment with decolourising charcoal and recrystallization from cyclohexane gave 6f (3.95g, 41%) as pale green crystals, m.p. 82.5-84C. 1H NMR (CDCl3) ? 1.06 (3H, t, J=7.2Hz), 1.75-1.94 (2H, m), 3.47 (3H, s), 3.74-3.81 (2H, m), 4.14-4.21 (2H, m), 4.27 (2H, t, J=6.6Hz), 6.68 (1H, d, J=9.3Hz), 7.00 (2H, d, J=8.8Hz), 7.76-7.88 (3H, m), 7.94 (1H, s). MS (APCI+) m/z 328 (M+H, 100%).

90008-50-7 6-Propoxypyridazin-3-amine 10511047, apyridazine compound, is more and more widely used in various.

Reference£º
Article; Ali, Abdelselam; Cablewski, Teresa; Francis, Craig L.; Ganguly, Ashit K.; Sargent, Roger M.; Sawutz, David G.; Winzenberg, Kevin N.; Bioorganic and Medicinal Chemistry Letters; vol. 21; 14; (2011); p. 4160 – 4163;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.5096-73-1,6-Chloropyridazine-3-carboxylic acid,as a common compound, the synthetic route is as follows.

5096-73-1, Procedure for synthesis of 6-chloro-N-(1 -cyano-1 -methyl-ethyl)pyridazine-3-carboxamide (Step-2) To a mixture of 6-chloropyridazine-3-carboxylic acid (0.770 g, 4.86 mmol) in DCM (10 mL) was added oxalyl chloride (0.629 g, 4.86 mmol) dropwise. DMF (0.050 mL) was added and the resulting reaction mixture was stirred at ambient temperature for 1 h. The reaction mixture was evaporated in vacuo to give the intermediate acid chloride (6-chloropyridazine-3-carbonyl – – chloride). To a mixture of 6-chloropyridazine-3-carbonyl chloride (0.835 g, 4.72 mmol) and Nu,Nu’- diisopropylethylamine (0.610 g, 4.72 mmol, 1 equiv.) in DCM (10 mL), was added 2-amino-2- methyl-propanenitrile (0.397 g, 4.72 mmol, 1 equiv.) dropwise. The resulting reaction mixture was stirred at ambient temperature for 18 h. The reaction mixture was then poured into water and extracted with DCM. The organics were combined and evaporated in vacuo and the crude product then chromatographed on silica eluting with 0-80% EtOAc in isohexane. Fractions containing product were evaporated to give the desired product as a white solid (606 mg, 75%). LC-MS: (positive ES MH+ 225/227).

5096-73-1 6-Chloropyridazine-3-carboxylic acid 6415762, apyridazine compound, is more and more widely used in various.

Reference£º
Patent; SYNGENTA PARTICIPATIONS AG; SYNGENTA LIMITED; PHADTE, Mangala; SONAWANE, Ravindra; HENNESSY, Alan Joseph; MORRIS, James Alan; BOEHMER, Jutta Elisabeth; LONGSTAFF, Adrian; LING, Kenneth; RUSSELL, Sally Elizabeth; DESSON, Timothy Robert; HOTSON, Matthew Brian; MOSELEY, Donn Warwick; WO2015/67701; (2015); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

6082-66-2, 3,4,6-Trichloropyridazine is a pyridazine compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

6082-66-2, (b) 2-[(3,6-Dichloro-4-pyridazinyl)oxy]ethanolA solution of ethylene glycol (55 ml) in tetrahydrofuran (200 ml) was treated at around O0C (ice bath cooling) with sodium hydride (60% dispersion in oil, 5.9 g) over 40 minutes. After the addition was complete, 3,4,6-trichloropyridazine (27 g) containing isomers of bromo-dichloropyridazine as impurity was added portionwise and washed in with more dry THF (50ml) and the mixture was stirred at O0C for 1 hour and then at room temperature overnight. The mixture was concentrated (to 1/3 volume) then diluted with aqueous sodium bicarbonate solution and extracted with chloroform (5x) and ethyl acetate (3x). The combined organic extracts were washed with water, dried over sodium sulphate and evaporated and the solids filtered off and washed with CHCI3 (x3) and dried in a vacuum oven overnight at 4O0C affording a white solid (25.5 g, 83%), containing some bromo-derivative (10-15%). MS (+ve ion electrospray) m/z 209/211 (MH+).MS (+ve ion electrospray) m/z 255/7 (MH+), bromo-derivative.

The synthetic route of 6082-66-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2007/71936; (2007); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem

50681-25-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50681-25-9,4-Pyridazinecarboxylic Acid,as a common compound, the synthetic route is as follows.

Example 47-1 : Synthesis of (2R,4S)-5-Biphenyl-4-yl-2-methyl-4-[(pyridazine-4- carbonyl)-amino]-pentanoic acid; To a stirred solution of pyridazine-4-carboxylic acid (21 mg, 0.17 mmol) in DMF (6 ml_) is added HOBT (26 mg, 0.17 mmol) and HBTU (65 mg, 0.17 mmol) and the mixture is stirred at room temperature for 10 minutes. (2R,4S)-4-Amino-5-biphenyl-4-yl-2-methyl-pentanoic acid ethyl ester hydrochloride (50 mg, 0.14 mmol) and DIEA (42 mg, 0.56 mmol) are added. After stirring the mixture at room temperature for 18 hours, water is added and the mixture is extracted three times with ethyl acetate. The combined organic layers are washed with water and brine then is dried over magnesium sulfate. The solvent is removed under reduced pressure to give the title compound; HPLC retention time 1.19 minutes (condition C); MS 390.3 (M+H); 1 H NMR (400 MHz, DMSO-d6): ? ppm 1 .08-1 .10 (d, J=7.07 Hz, 3H), 1 .59-1 .66 (m, 1 H), 1 .88-1 .95 (m, 1 H), 2.46-2.53 (m, 1 H), 2.85-2.87 (d, J=6.82 Hz, 2H), 4.22- 4.30 (m, 1 H), 7.29-7.32 (m, 2H), 7.33-7.36 (m, 1 H), 7.42-7.46 (m, 2H), 7.57-7.59 (m, 2H), 7.62-7.65 (m, 2H), 7.91 -7.93 (q, J=2.27 Hz, 1 H), 8.76-8.78 (d, J=8.59 Hz, 1 H), 9.41 -9.43 (m, 1 H), 9.45-9.46 (m, 1 H), 12.09 (s, 1 H).

As the paragraph descriping shows that 50681-25-9 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; COPPOLA, Gary Mark; IWAKI, Yuki; KARKI, Rajeshri Ganesh; KAWANAMI, Toshio; KSANDER, Gary Michael; MOGI, Muneto; SUN, Robert; WO2010/136474; (2010); A2;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem